EDN1 and pulmonary arterial hypertension: In the past 2 decades, PAH-targeted medical therapy for major 3 pathways have been developed, including prostacyclin, endothelin-1 (ET-1), and nitric oxide (NO), with resultant marked improvement of survival of PAH patients [2–5].